Features of the State of Cellular and Humoral Markers of the Immune System in Breast Cancer among Women in Aktobe Region
DOI:
https://doi.org/10.3889/oamjms.2022.9197Keywords:
Breast Cancer, Cellular and Humoral Immunity, MarkersAbstract
Abstract
BACKGROUND: Globally, breast cancer is considered one of the most common cancers among women and the second most common cancer worldwide. Breast cancer is also more common in developed countries, and its prevalence is increasing globally by 2% each year.
AIM: The aim of this study is to determine the features of the state of cellular and humoral markers of the immune system, as well as the relationship of specific and nonspecific immunity in women in the compared groups in breast cancer in Aktobe region.
METHODS: The study was conducted on 251 patients at Medical Center of West Kazakhstan Marat Ospanov Medical University with the established diagnosis of breast cancer. The study period was 3 years (2018-2020). Acknowledgements. Authors declare the absence of conflict of interest. The study is funded by the Ministry of Education and Science of the Republic of Kazakhstan project IRN 0118RK01065. Two groups of patients were formed, among them in the control group - BC before chemotherapy and in the main group - BC after chemotherapy. To address the objectives, in addition to the general clinical study, all patients were conducted immune system study. CD3+CD19-, CD3-CD19+, CD4+CD8-,CD4-CD8+, IRI, CD3+HLA-DR+, NK(CD16+56+), CD3+/CD16+56+ ; and to determine humoral immunity, the content of JgM, JgG, JgA were determined.
RESULTS: Correlation analysis revealed a strong positive relationship between IRI and T helper (CD4+CD8-) (r=0.79; p≤0.05) and a strong negative correlation between T cytotoxic lymphocyte (CD4-CD8+) and IRI (r= -0.8; p≤0.05) in both patient groups. The ratio of the two T cell subpopulations CD4+/T cell CD8+ is at the regulatory T cell level (IRI). A direct median correlation between T lymphocyte (CD3+CD19-) and T killer (CD3+/CD16+56+) r= 0.35; (p≤0.05) was found, which indicates an integral regulatory role of natural killer cells in immune system function. The following coorelation analysis showed a weak negative association between cellular and humoral immunity in the control group of women between T cytotoxic lymphocytes (CD4-CD8+) and IgG(r=-0.2; p≤0.05). Further, the relationship revealed between cellular and humoral immunity in the main group between IG M and NK cells (r= -0.2; p≤0.05).
CONCLUSION: It can be assumed that identifying the possibility of altering the antitumor immune response before and after chemotherapy in patients with a primary breast tumor may set the stage for its early detection and application of targeted chemoprophylaxis.
Abstract
BACKGROUND: Globally, breast cancer is considered one of the most common cancers among women and the second most common cancer worldwide. Breast cancer is also more common in developed countries, and its prevalence is increasing globally by 2% each year.
AIM: The aim of this study is to determine the features of the state of cellular and humoral markers of the immune system, as well as the relationship of specific and nonspecific immunity in women in the compared groups in breast cancer in Aktobe region.
METHODS: The study was conducted on 251 patients at Medical Center of West Kazakhstan Marat Ospanov Medical University with the established diagnosis of breast cancer. The study period was 3 years (2018-2020). Acknowledgements. Authors declare the absence of conflict of interest. The study is funded by the Ministry of Education and Science of the Republic of Kazakhstan project IRN 0118RK01065. Two groups of patients were formed, among them in the control group - BC before chemotherapy and in the main group - BC after chemotherapy. To address the objectives, in addition to the general clinical study, all patients were conducted immune system study. CD3+CD19-, CD3-CD19+, CD4+CD8-,CD4-CD8+, IRI, CD3+HLA-DR+, NK(CD16+56+), CD3+/CD16+56+ ; and to determine humoral immunity, the content of JgM, JgG, JgA were determined.
RESULTS: Correlation analysis revealed a strong positive relationship between IRI and T helper (CD4+CD8-) (r=0.79; p≤0.05) and a strong negative correlation between T cytotoxic lymphocyte (CD4-CD8+) and IRI (r= -0.8; p≤0.05) in both patient groups. The ratio of the two T cell subpopulations CD4+/T cell CD8+ is at the regulatory T cell level (IRI). A direct median correlation between T lymphocyte (CD3+CD19-) and T killer (CD3+/CD16+56+) r= 0.35; (p≤0.05) was found, which indicates an integral regulatory role of natural killer cells in immune system function. The following coorelation analysis showed a weak negative association between cellular and humoral immunity in the control group of women between T cytotoxic lymphocytes (CD4-CD8+) and IgG(r=-0.2; p≤0.05). Further, the relationship revealed between cellular and humoral immunity in the main group between IG M and NK cells (r= -0.2; p≤0.05).
CONCLUSION: It can be assumed that identifying the possibility of altering the antitumor immune response before and after chemotherapy in patients with a primary breast tumor may set the stage for its early detection and application of targeted chemoprophylaxis.
Abstract
BACKGROUND: Globally, breast cancer is considered one of the most common cancers among women and the second most common cancer worldwide. Breast cancer is also more common in developed countries, and its prevalence is increasing globally by 2% each year.
AIM: The aim of this study is to determine the features of the state of cellular and humoral markers of the immune system, as well as the relationship of specific and nonspecific immunity in women in the compared groups in breast cancer in Aktobe region.
METHODS: The study was conducted on 251 patients at Medical Center of West Kazakhstan Marat Ospanov Medical University with the established diagnosis of breast cancer. The study period was 3 years (2018-2020). Acknowledgements. Authors declare the absence of conflict of interest. The study is funded by the Ministry of Education and Science of the Republic of Kazakhstan project IRN 0118RK01065. Two groups of patients were formed, among them in the control group - BC before chemotherapy and in the main group - BC after chemotherapy. To address the objectives, in addition to the general clinical study, all patients were conducted immune system study. CD3+CD19-, CD3-CD19+, CD4+CD8-,CD4-CD8+, IRI, CD3+HLA-DR+, NK(CD16+56+), CD3+/CD16+56+ ; and to determine humoral immunity, the content of JgM, JgG, JgA were determined.
RESULTS: Correlation analysis revealed a strong positive relationship between IRI and T helper (CD4+CD8-) (r=0.79; p≤0.05) and a strong negative correlation between T cytotoxic lymphocyte (CD4-CD8+) and IRI (r= -0.8; p≤0.05) in both patient groups. The ratio of the two T cell subpopulations CD4+/T cell CD8+ is at the regulatory T cell level (IRI). A direct median correlation between T lymphocyte (CD3+CD19-) and T killer (CD3+/CD16+56+) r= 0.35; (p≤0.05) was found, which indicates an integral regulatory role of natural killer cells in immune system function. The following coorelation analysis showed a weak negative association between cellular and humoral immunity in the control group of women between T cytotoxic lymphocytes (CD4-CD8+) and IgG(r=-0.2; p≤0.05). Further, the relationship revealed between cellular and humoral immunity in the main group between IG M and NK cells (r= -0.2; p≤0.05).
CONCLUSION: It can be assumed that identifying the possibility of altering the antitumor immune response before and after chemotherapy in patients with a primary breast tumor may set the stage for its early detection and application of targeted chemoprophylaxis.
Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7-33. https://doi.org/10.3322/caac.21708. PMid:35020204
Simonian M, Ghaffari MH, Negahdari B. Immunotherapy for breast cancer treatment. Iran Biomed J. 2021;25(3):140-56. https://doi.org/10.29252/ibj.25.3.140 PMid: 33724757
Jaafar M. Diversity of breast carcinoma: Histological subtypes and clinical relevance. Clin Med Insights Pathol. 2015;8:23-31. https://doi.org/10.4137/CPath.S31563 PMid:26740749
Zabotina TN, Chertkova AI, Borunova AA, Zakharova EN, Shoua EK, Artamonova EV, et al. Relationship of lymphocyte subpopulations in breast cancer patients with treatment results. Russian J Biother. 2021;20:25-33. https://doi.org/10.17650/1726-9784-2021-20-3-25-33
Harbeck N, Penault-Llorca F, Cortes J, Gnant M, Houssami N, Poortmans P, et al. Breast cancer. Nat Rev Dis Primers. 2019;5(1):66. https://doi.org/10.1038/s41572-019-0111-2 PMid:31548545
Oshi M, Asaoka M, Tokumaru Y, Angarita FA, Yan L, Matsuyama R, et al. Abundance of regulatory T cell (Treg) as a predictive biomarker for neoadjuvant chemotherapy in triple-negative breast cancer. Cancers (Basel). 2020;12(10):3038. https://doi.org/10.3390/cancers12103038 PMid:33086518
Cimino-Mathews A, Foote JB, Emens LA. Immune targeting in breast cancer. Oncology (Williston Park). 2015;9(5):375-85. PMid:25979549
Cruz-Merino L, Chiesa M, Caballero R, Rojo F, Palazón N, Carrasco FH, et al. Breast cancer immunology and immunotherapy: Current status and future perspectives. Int Rev Cell Mol Biol. 2017;331:1-53. https://doi.org/10.1016/bs.ircmb.2016.09.008 PMid:28325210
Cruz-Merino L, Palazón-Carrión N, Henao-Carrasco F, Nogales- Fernández E, Álamo-de la Gala M, Vallejo-Benítez A, et al. New horizons in breast cancer: The promise of immunotherapy. Clin Transl Oncol. 2019;21(2):117-25. https://doi:10.1007/s12094-018-1907-3. PMid:29916188
Farhood B, Najafi M, Mortezaee K. CD8+ cytotoxic T lymphocytes in cancer immunotherapy. J Cell Physiol. 2019;234(6):8509-21. https://doi.org/10.1002/jcp.27782 PMid:30520029
Speiser DE, Ping-Chih Ho PC, Verdeil G. Regulatory circuits of T cell function in cancer. Nat Rev Immunol. 2016;16(10):599-611. https://doi.org/10.1038/nri.2016.80 PMid:27526640
O’Donnell JS, Teng MW, Smyth MJ. Cancer immunoediting and resistance to T cell- based immunotherapy. Nat Rev Clin Oncol. 2019;16(3):151-67. https://doi.org/10.1038/s41571-018-0142-8 PMid:30523282
de Aquino MT, Malhotra A, Mishra MK, Shanker A. Challenges and future perspectives of T cell immunotherapy in cancer. Immunol Lett. 2015;166(2):117-33. https://doi.org/10.1016/j.imlet.2015.05.018 PMid:26096822
Zhang L, Liu M, Yang S, Wang J, Feng X, Han Z. Natural killer cells: Of-the-shelf cytotherapy for cancer immunosurveillance. Am J Cancer Res. 2021;11(4):1770-91. PMid:33948388
Huang Y, Ma C, Zhang Q, Ye J, Wang F, Zhang Y, et al. CD4+ and CD8+ T cells have opposing roles in breast cancer progression and outcome. Oncotarget. 2015;6(19):17462-78. https://doi.org/10.18632/oncotarget.3958 PMid:25968569
Liu M, Meng Y, Zhang L, Han Z, Feng X. High-efficient generation of natural killer cells from peripheral blood with preferable cell vitality and enhanced cytotoxicity by combination of IL-2, IL-15 and IL-18. Biochem Biophys Res Commun. 2021;534:149-56. https://doi.org/10.1016/j.bbrc.2020.12.012 PMid:33309274
Mittal D, Gubin MM, Schreiber RD, Smyth MJ. New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape. Curr Opin Immunol. 2014;27:16-25. https://doi.org/10.1016/j.coi.2014.01.004 PMid:24531241
Siska PJ, Rathmell JC. T cell metabolic fitness in antitumor immunity. Trends Immunol. 2015;36(4):257-64. https://doi.org/10.1016/j.it.2015.02.007 PMid:25773310
Valachis A, Nearchou AD, Lind P. Surgical management of breast cancer in BRCA- mutation carriers: A systematic review and meta-analysis. Breast Cancer Res Treat. 2014;144(3):443-55. https://doi.org/10.1007/s10549-014-2890-1 PMid:24567198
Siu AL, U.S. Preventive Services Task Force. Screening for breast cancer: US preventive services task force recommendation statement. Ann Intern Med. 2016;164(4):279-96. https://doi.org/10.7326/M15-2886 PMid:26757170
Carmi Y, Spitzer MH, Linde IL, Burt BM, Prestwood TR, Perlman N, et al. Allogeneic IgG combined with dendritic cell stimuli induces anti-tumor T cell immunity. Nature. 2015;521(7550):99-104. https://doi.org/10.1038/nature14424 PMid:25924063
Garaud S, Zayakin P, Buisseret L, Rulle U, Silina K, de Wind A, et al. Antigen specificity and clinical significance of IgG and IgA autoantibodies produced in situ by tumor-infiltrating B cells in breast cancer. Front Immunol. 2018;9:2660. https://doi.org/10.3389/fimmu.2018.02660 PMid:30515157
Liu X, Zheng D, Wu Y, Luo CH, Fan Y, Zhong X, et al. Treatment patterns and outcomes in older women with early breast cancer: A population-based cohort study in China. BMC Cancer. 2021;21(1):226. https://doi.org/10.1186/s12885-021-07947-w PMid:33673816
Chertkova AI, Zabotina TN, Tsiklauri VT, Zakharova EN, Tabakov DV, Borunova AA, et al. Age related features of systemic antitumor immune response in patients with primary operable breast cancer and cancer of the oral mucosa. Russ J Biother. 2020;19:81-8. https://doi.org/10.17650/1726-9784-2019-19-1-81-88
Wu S, Fu T, Jiang Y, Shao Z. Natural killer cells in cancer biology and therapy. Mol Cancer. 2020;19(1):120. https://doi.org/10.1186/s12943-020-01238-x PMid:32762681
Wu F, Xie M, Hun M, She Z, Li C, Luo S, et al. Natural killer cell-derived extracellular vesicles: Novel players in cancer immunotherapy. Front Immunol. 2021;12:658698. https://doi.org/10.3389/fimmu.2021.658698 PMid:34093547
Saraiva DP, Jacinto A, Borralho P, Braga S, Cabral MG. HLA-DR in cytotoxic T lymphocytes predicts breast cancer patients’ response to neoadjuvant chemotherapy. Front Immunol. 2018;9:2605. https://doi.org/10.3389/fimmu.2018.02605 PMid:30555458
Khan M, Arooj S, Wang H. NK cell-based immune checkpoint inhibition. Front Immunol. 2020;11:167. https://doi.org/10.3389/fimmu.2020.00167 PMid:32117298
Chiossone L, Dumas PY, Vienne M, Vivier E. Natural killer cells and other innate lymphoid cells in cancer. Nat Rev Immunol. 2018;18(11):671-88. https://doi.org/10.1038/s41577-018-0061-z PMid:30209347
Savchenko A, Modestov AA, Moshev AV, Tonacheva OG, Borisov AG. Flow cytometry of NK and NKT cells in patient with renal cell carcinoma. Russian J Immunol. 2014;8(17):1012-18.
Sánchez-Margalet V, Barco-Sánchez A, Vilariño-García T, Jiménez-Cortegana C, Pérez- Pérez A, Henao-Carrasco F, et al. Circulating regulatory T cells from breast cancer patients in response to neoadjuvant chemotherapy. Transl Cancer Res. 2019;8(1):59-65. https://doi.org/10.21037/tcr.2018.12.30 PMid:35116734
Ohue Y, Nishikawa H. Regulatory T (Treg) cells in cancer: Can Treg cells be a new therapeutic target? Cancer Sci. 2019;110(7):2080-9. https://doi.org/10.1111/cas.14069 PMid:31102428
Downloads
Published
How to Cite
License
Copyright (c) 2022 Azhar Zhexenova, Aiman Kaldybaeva, Ainur Amanzholkyzy, Gulaim Taskozhina, Saulesh Kurmangalieva, Altyn Almagambetova, Gulnara Gubasheva, Gulbanu Mukyshova, Dina Yegisbaeva (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
http://creativecommons.org/licenses/by-nc/4.0
